![Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis](https://www.mdpi.com/biomedicines/biomedicines-10-01575/article_deploy/html/images/biomedicines-10-01575-g002-550.jpg)
Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
![Cancers | Free Full-Text | Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives Cancers | Free Full-Text | Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives](https://www.mdpi.com/cancers/cancers-13-03715/article_deploy/html/images/cancers-13-03715-g001.png)
Cancers | Free Full-Text | Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
![PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/62/12/1747/F1.large.jpg)
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
![PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00259-020-05040-1/MediaObjects/259_2020_5040_Fig1_HTML.png)
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging
![Circulating androgen receptor gene amplification and resistance to 177Lu- PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial | British Journal of Cancer Circulating androgen receptor gene amplification and resistance to 177Lu- PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01508-5/MediaObjects/41416_2021_1508_Fig2_HTML.png)
Circulating androgen receptor gene amplification and resistance to 177Lu- PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial | British Journal of Cancer
![Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James](https://journals.sagepub.com/cms/10.1177/17588359231177018/asset/images/large/10.1177_17588359231177018-fig1.jpeg)
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James
![PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | European Journal of Nuclear Medicine and Molecular Imaging PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | European Journal of Nuclear Medicine and Molecular Imaging](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00259-022-06089-w/MediaObjects/259_2022_6089_Fig1_HTML.png)
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | European Journal of Nuclear Medicine and Molecular Imaging
![Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-023-10725-5/MediaObjects/12885_2023_10725_Fig1_HTML.png)
Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text
![PSMA PET/CT und PET/MRT in der Diagnostik des Prostatakarzinoms • Fachportal für Wehrmedizin & Wehrpharmazie PSMA PET/CT und PET/MRT in der Diagnostik des Prostatakarzinoms • Fachportal für Wehrmedizin & Wehrpharmazie](https://wehrmed.de/media/story/3401/contentmedium-04-abb-2-psma-pet-ct-beckenlymphknoten_hires.jpg)
PSMA PET/CT und PET/MRT in der Diagnostik des Prostatakarzinoms • Fachportal für Wehrmedizin & Wehrpharmazie
![Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13550-023-01033-x/MediaObjects/13550_2023_1033_Fig1_HTML.jpg)
Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text
![Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy](https://www.thno.org/v10/p7645/toc.jpg)
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
![Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)](https://www.frontiersin.org/files/Articles/1059122/fmed-09-1059122-HTML-r1/image_m/fmed-09-1059122-g001.jpg)
Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
![History of PSMA Power Technology Roadmap: from AAA TripTik® to Google Maps® - Ritu Sodhi - APEC | IEEETV History of PSMA Power Technology Roadmap: from AAA TripTik® to Google Maps® - Ritu Sodhi - APEC | IEEETV](https://ieeetv.ieee.org/assets/video-images/large/APEC-2022-Poster-Frame-05.png)
History of PSMA Power Technology Roadmap: from AAA TripTik® to Google Maps® - Ritu Sodhi - APEC | IEEETV
![Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James](https://journals.sagepub.com/cms/10.1177/17588359231177018/asset/images/large/10.1177_17588359231177018-fig2.jpeg)
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James
![177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet 177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/14225012-ffb5-48bd-ac5a-4468b251c769/gr1.gif)
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet
![Pharmaceutics | Free Full-Text | Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer Pharmaceutics | Free Full-Text | Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-02166/article_deploy/html/images/pharmaceutics-14-02166-g001.png)
Pharmaceutics | Free Full-Text | Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
![PDF] Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer | Semantic Scholar PDF] Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5818ab72f095addb203c1f123e850b902a52d548/4-Table3-1.png)